Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control (BRCA-ERC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Austria,Sweden,Czechia,United Kingdom
Call: ERC Advanced Grant (ERC-2016-ADG, 2016)
Start date: 2017-09-01
End date: 2023-05-31
Duration (months): 69.0
Total project cost (EUR): 2497841.0
EU funding (EUR): 1115793.0
Participants: 5
Project status: SIGNED

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Keywords: cancer and its biological basis,women s cancers,breast cancer,ovarian cancer,brca1,2 mutation,cell non autonomous,hormones,prevention,early diagnosis,surrogate markers
Customisable Bioink Technology Platform (CBIT)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: United Kingdom
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-03-01
End date: 2017-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

3D cell culture and 3D Bioprinting have become crucial to the development of health and life science research. 3D cell culture has enabled more accurate cell screening, drug and biosensor discovery, tissue engineering, and development of cell lines. One of the major challenges to culturing complex tissues is producing detailed matrix morphologies with optimised pore size, mechanical properties and biocompatibility. Many of the bioink 3D matrices under development do not sufficiently address the physical (mechanical properties), chemical and biological (cell-matrix interactions) complexity required for sucessful 3D culture. PGD have developed an eight amino acid sequence peptide that self-assembles and forms a hydrogel in the presence of a salt solution. This platform technology is commerically available for 3D culture or tissue engineering research and can be purchased as a liquid or spray. PGD are now investigating the feasibility of producing a bioink. PGD will produce a bioink and disposable mixing chamber that can be 3D printed and support cell viability. For additive manufacturing to break through in the life sciences and pharma industry, a complete package must be provided, including ready to use inks that are true 3D ECM mimics and compatible with processing methods. They must not impede staining/assays or optical/electrochemical detection of cells. At present, there is no bioink on the market that is suitable for large scale use in the pharmaceutical and life science industries.

Keywords: bioink,additive manufacturing,3d cell culture
Tracing ancient microbial cells embedded in silica (TRACES)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Earth system science
Panel description: Physical geography, geology, geophysics, atmospheric sciences, oceanography, climatology, cryology, ecology, global environmental change, biogeochemical cycles, natural resources management
Countries involved: France
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-05-01
End date: 2020-09-30
Duration (months): 65.0
Total project cost (EUR): 1999250.0
EU funding (EUR): 1999250.0
Participants: 2
Project status: CLOSED

Reconstructing the nature and habitat of early life is a difficult task that strongly depends on the study of rare microfossils in the ancient rock record. The preservation of such organic structures critically depends on rapid entombment in a mineral matrix. Throughout most of Earth’s history the oceans were silica-supersaturated, leading to precipitation of opal deposits that incorporated superbly preserved microbial cells. As we trace this record of life back in deep time, however, three important obstacles are encountered; 1) microorganisms lack sufficient morphologic complexity to be easily distinguished from each other and from certain abiologic microstructures, 2) the ancient rock record has been subjected to increased pressures and temperatures causing variable degradation of different types of microorganism, and 3) early habitats of life were dominated by hydrothermal processes that can generate abiologic organic microstructures. TRACES will study the critical transformations that occur when representative groups of microorganisms are subjected to artificial silicification and thermal alteration. At incremental steps during these experiments the (sub)micron-scale changes in structure and composition of organic cell walls are monitored. This will be compared with fossilized life in diagenetic hot spring sinters and metamorphosed Precambrian chert deposits. The combined work will lead to a dynamic model for microfossil transformation in progressively altered silica-matrices. The critical question will be answered whether certain types of microorganisms are more likely to be preserved than others. In addition, the critical nano-scale structural differences will be determined between abiologic artefacts – such as carbon coatings on botryoidal quartz or adsorbed carbon on silica biomorphs – and true microfossils in hydrothermal cherts. This will provide a solid scientific basis for tracing life in the oldest, most altered part of the rock record.

Keywords: microorganism,cell,microfossil,kerogen,morphology,opal,chert,sinter,quartz,diagenesis,metamorphism,hydrothermal,permineralization,archean,proterozoic,precambrian
Voices Of Individuals: Collectively Exploring Self-determination (VOICES)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Ireland
Call: ERC Starting Grant (ERC-2014-STG, 2014)
Start date: 2015-06-01
End date: 2018-11-30
Duration (months): 42.0
Total project cost (EUR): 891386.0
EU funding (EUR): 891386.0
Participants: 1
Project status: CLOSED

The right to make one’s own decisions and to have these decisions respected by law is a basic human freedom which most adults take for granted. However, for many people with disabilities (especially people with intellectual, psycho-social and other cognitive disabilities) this fundamental right has been denied – informally, in the private sphere, and formally, in the public sphere through States’ laws and policies. Since the entry into force of the UN Convention on the Rights of Persons with Disabilities, there is an emerging consensus in human rights discourse that all people, regardless of their decision-making skills, should enjoy ‘legal capacity’ on an equal basis—that is, the right to be recognised as a person before the law and the subsequent right to have one’s decisions legally recognised. To date most of the literature on how this right should be realised has been developed by non-disabled scholars without the direct input of people with disabilities themselves. The VOICES project will take a radical approach to develop new law reform ideas based on this concept of ‘universal legal capacity.’ Its primary objective is to develop reform proposals based on the lived experience of disability. The project will support individuals who self-identify as disabled to develop personal narratives about their experiences in exercising, or being denied, legal capacity. Through a collaborative process, legal and social science scholars will then work with people with disabilities to develop their personal narratives to frame and ground concrete proposals for law reform in previously unexplored areas – including consent to sex, contractual capacity, criminal responsibility and consent to medical treatment. In this way, the legitimacy of people with disabilities’ perspectives on the options for law reform will be validated, and this will create a powerful argument for legal change.
Scalable energy efficiency modules integrating both energy recovery and passive cooling systems for the solar photovoltaic industry (LightCatcher)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The optimisation of energy efficiency and the increase of renewable energies in the energy mix are key elements for the clean energy transition to fight global warming. Solar energy is the most abundant energy source on Earth and solar photovoltaics (PV) is the third most important renewable source in terms of global installed capacity. But PV energy conversion efficiency is below 20%, while 80% of the sun’s radiation energy is lost in form of waste heat. Furthermore, the heat excess on PV modules reduces their energy conversion efficiency and the high PV module temperatures under in real-life environment reduce the lifecycle of PV modules and increases maintenance cost. LightCatcher is a disruptive solution that simultaneously addresses PV energy efficiency and the problems created by waste heat in the solar PV industry: i) recycling of waste heat into electricity and ii) passive cooling of the PV device. The combination of both effects leads to solar-to-electricity efficiencies of up to 80%. By maximising electricity production and equipment lifecycle, while reducing CAPEX, maintenance cost, and ROI time LightCatcher will reduce PV levelized cost of energy in over 33%, helping the PV industry to become cost competitive against traditional energy sources. LightCatcher is highly scalable to find direct applications for the improvement of energy efficiency in a vast range of applications such as electric vehicles, air conditioning, or as a solution for cooling, and energy recovery and reuse in industry processes. LightCatcher addresses the global market for PV Balance of Systems (BOS) that was valued over €31.2bn in 2018 and is projected to reach €71.1bn by 2023, growing at a CAGR of 21.0% from 2018 to 2023. By successfully implementing the LightCatcher project, we expect to create a measurable impact on Heatconv quantified as increased accumulated revenue of €102.6m and profit of €64.8m, creating 55 FTE in our company with 20.46 ROI by year 5 after project closure.

Keywords: waste heat recovery,levelized cost of energy,lcoe,cooling management,solar energy,renewable energy
European Researchers' Night 2021 in Malopolska (ECOResearchers4Earth)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European researchers' Night
Action type: Marie Skłodowska-Curie actions
Countries involved: Poland,Poland,Poland,Poland
Call: European Researchers' Night (H2020-MSCA-NIGHT-2020bis, 2020)
Start date: 2021-04-01
End date: 2021-11-30
Duration (months): 8.0
Total project cost (EUR): 168445.0
EU funding (EUR): 89887.5
Participants: 10
Project status: CLOSED

European Researchers' Night (ERN) in Malopolska 2021 (Malopolska Researchers' Night) will be organised for the 15th time in our region. The event will be held in the hybrid formula (online and stationary activities) to response the participants needs and current pandemic situation. Such formula enable to attract larger group of people. Scale of the event is huge to show the wide scientific heritage and achieve project's goals: 8 cities of the Malopolska Region (Krakow, Tarnow, Nowy Sacz, Niepolomice, Oswiecim, Skawina, Chrzanow and Limanowa), approx. 60 locations in ca. 35 partner institutions (both those included in the project consortium and other partners involved in the ERN in Malopolska), approx. 1,800 different activities (including e.g. interactive workshops, demos and experiments, face to face meetings with researchers, science shows etc.) prepared by over 2,000 researchers, R&D employees and students in cooperation with 80 science clubs. ERN 2021 will be organized under the slogan "Researchers are changing our world". Particular emphasis will be placed on the role of researchers in the fight against various environmental threats, as well as against air pollution (incl. smog and climate changes) - they will share their discoveries with the ERN participants that aim to save our planet (incl. activities related to European Green Deal). An important distinction of the ERN among other events is that we focus 100% on interactivity. During the ERN, the researchers present their work combining learning with entertainment (edutainment), to make children and young people as passionate about science as possible. But the participants themselves will feel like real researchers performing unusual experiments under the watchful eye of their mentors. The project has European dimension: due to its broad and diversified awareness campaign, we estimate that 4.5 million people will be made aware of the project and its objectives. Duration of the project: 1.04.-30.11.2021.

Keywords: researchers,science,society,european dimension,scientific career,workshops,laboratories,experiments,demonstrations,meetings with researchers,ecology,climate,environment
B4P No-Waste Polymers: Architected for performance, loaded with circularity (B4PNOW)

Framework: Horizon 2020 — Societal Challenges
Action type: SME instrument
Countries involved: Belgium
Call: H2020-EIC Accelerator pilot –SME Instrument - Green Deal (H2020-EIC-SMEInst-2018-2020-4, 2020)
Start date: 2020-12-01
End date: 2022-11-30
Duration (months): 24.0
Total project cost (EUR): 1147867.5
EU funding (EUR): 803507.0
Participants: 1
Project status: CLOSED

B4Plastics (B4P) https://www.b4plastics.com/en is a bio-polymer architecture company, committed to making the greenest plastics ever developed. B4P Polymers have beaten world records in strength versus degradation: Despite being completely biodegradable in a controlled way ranging from years to even days, the biopolymers are designed for the highest mechanical strength, outcompeting fossil materials like traditional polyesters and polyamides. This allows for circularity “on demand”, a key concept in B4P’s polymer design: if the afterlife allows it we design it to be recycled. On the other hand, if the after-life situation demands it (if it will end up as pollution), we design it to completely degrade, triggered by its specific end-of-life situation. That way, B4P has gained a unique position to change the status quo of the plastics economy, already having market-leading customers, such as STIHL, Huntsman, Capri-Sun, Lankhorst Euronete Portugal, Nike, 3M and Patagonia. B4P Polymers, completely aligned with the European Green Deal, are becoming game-changers in the plastic industry with an unprecedented balance in cost, performance, and ecology. B4P wants to move from R&D company / developer to commercial supplier. B4PNOW will serve this goal by moving the technology from TRL 6 to 8, and launch two first proprietary polymer families: • FortePlastics combines unprecedented material strength with full degradability – entering a € 42+ billion market. • TriggerPlastics has unique controllable (up to the world’s fastest) degradability – entering a € 300+ billion market. With the EIC support, B4P will become the first unicorn bioplastics company (>1 billion € turnover) in the world in 2030. This allows B4P to prevent 8 million tons of plastic waste that results in 1,5 million ton of micro-plastics leaking into the ocean, yearly. B4PNOW!

Keywords: biobased,building blocks,bioplastics,polymerization,designed,customized,biodegradable,recyclable,value chain disruption business model microplastics waste reduction circular economy bioeconomy
Scalable and efficient production of functionalized, high-performance solution-processable graphene-materials (HIPER-G)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2017-09-01
End date: 2019-02-28
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The worldwide increasing need for resources and energy as well as the foreseeable depletion of fossil fuels has led scientists into a race towards finding cleaner, more efficient and sustainable technologies. Graphene is believed to be able to play a crucial role in these developments due to its outstanding properties like excellent conductivity, mechanical strength, flexibility and chemical stability. A possible large-scale application is foreseen in polymer composites, where next to increased mechanical stability, graphene can introduce additional functionalities such as conductivity, antistatic properties or flame retardancy to specialty and commodity polymers. In addition, the potential to integrate cheap graphene-based, printed sensors, actuators, or networking capabilities into every-day products opens up completely new fields of application (e.g. the Internet of Things vision). Current industrial preparation techniques are available to provide graphene at large scale but the materials suffer from drawbacks in terms of processability, which is why despite the great potential, only a very limited number of graphene-enhanced products are available on the market. Recently, we were able to demonstrate a novel technology for the functionalization of graphene. With this approach, we are now focusing to produce functionalized graphene with tailorable properties and improved processability. This breakthrough will open up new possibilities and prospects for the application of graphene. To exploit the potential impact of this approach we are aiming to prove the usability of our functionalized graphene in different applications in cooperation with experienced partners from industry.

Keywords: graphene,graphene production,functionalized graphene,up scaling,electrochemical exfoliation,conductive inks,printed electronics,wearable electronics,graphene composites,sustainable processing
IonoChem: A new and highly efficient cross membrane drug delivery strategy (IonoChem)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Germany
Call: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2015, 2015)
Start date: 2015-09-01
End date: 2016-02-29
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Many drugs are designed to target molecules inside cells. Due to the hydrophobic nature of the cell membranes however not all types of drugs can enter the cells in sufficient quantities. Thus large amounts of drug need to be administered which can lead to highly toxic systemic effects for the patient. Furthermore, new classes of therapeutics such as RNA- and DNA-based drugs require advanced delivery techniques to reach their intracellular targets. Ionovation’s proprietary IonoChem technology will provide a novel and highly effective solution to this problem by adding lipohilic “tails” directly to drug molecules at a one-on-one ratio. These “tails” allow drugs to easily pass through the cell membrane. As part of a service offer Ionovation will work with clients to identify the most effective tail for a particular molecule, and will also perform the lipophilization. The IonoChem platform will enable Ionovation GmbH (a manufacturer of experimental set-ups for the analysis of biological membranes) to enter the market for drug delivery technologies, thus creating a new line of business for the company. IonoChem will target the market for drug delivery systems, which was valued at US$151 billion in 2013. Market segments for initial introduction of the technology include RNAi drug delivery (a market worth US $11,7 billion in 2013) and drugs withdrawn from the market (eg Vioxx with 2.5 billion US $ annual global sales). Objectives of the phase I project include analysis of customer needs (pricing, expected turn-around times etc.), refinement of business model (licensing/fee for use model for contract manufacturers vs. service offer with production facilities at Ionovation’s head quarters); search for a suitable contract manufacturer for the phase II activities and the elaboration of a business plan. Phase II objectives include upscaling of the production under GMP conditions, establishment of contact to customers and the qualification of IonoChem in a preclinical setting.

Keywords: drug delivery,lipohilization,rna therapeutics,dna therapeutics,toxic systemic effects